Literature DB >> 27071153

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Jens Kuhle, Christian Barro, Ulf Andreasson, Tobias Derfuss, Raija Lindberg, Åsa Sandelius, Victor Liman, Niklas Norgren, Kaj Blennow, Henrik Zetterberg.   

Abstract

BACKGROUND: Neuronal damage is the morphological substrate of persisting neurological disability. Neurofilaments (Nf) are specific cytoskeletal proteins of neurons and their quantification has shown encouraging results as a biomarker for axonal injury.
METHODS: We aimed at comparing a widely used conventional ELISA for Nf light chain (NfL) with an electrochemiluminescence-based method (ECL assay) and a newly developed single-molecule array (Simoa) method in clinically relevant cerebrospinal fluid (CSF) and serum samples.
RESULTS: Analytical sensitivity was 0.62 pg/mL for Simoa, 15.6 pg/mL for the ECL assay, and 78.0 pg/mL for the ELISA. Correlations between paired CSF and serum samples were strongest for Simoa (r=0.88, p<0.001) and the ECL assay (r=0.78, p<0.001) and weaker for ELISA measurements (r=0.38, p=0.030). CSF NfL measurements between the platforms were highly correlated (r=1.0, p<0.001). Serum NfL levels were highly related between ECL assay and Simoa (r=0.86, p<0.001), and this was less visible between ELISA-ECL assay (r=0.41, p=0.018) and ELISA-Simoa (r=0.43, p=0.013). Multiple sclerosis (MS) patients had significantly higher serum NfL levels than controls when measured with Simoa (p=0.001) but not with the other platforms.
CONCLUSIONS: We found Simoa to be more sensitive than ELISA or the ECL assay. Our results support the feasibility of quantifying NfL in serum; the results correlate with the more-established CSF NfL test. The highly sensitive Simoa technology deserves further studies in larger patient cohorts to clarify whether serum NfL could be used in the future to measure disease severity and determine prognosis or response to treatment interventions in neurological diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27071153     DOI: 10.1515/cclm-2015-1195

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  177 in total

1.  Serum NfL (Neurofilament Light Chain) Levels and Incident Stroke in Adults With Diabetes Mellitus.

Authors:  Frederick K Korley; Jason Goldstick; Mitra Mastali; Jennifer E Van Eyk; William Barsan; William J Meurer; Jeremy Sussman; Hayley Falk; Deborah Levine
Journal:  Stroke       Date:  2019-05-29       Impact factor: 7.914

2.  Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study.

Authors:  Carlo Wilke; Friedemann Bender; Stefanie N Hayer; Kathrin Brockmann; Ludger Schöls; Jens Kuhle; Matthis Synofzik
Journal:  J Neurol       Date:  2018-05-08       Impact factor: 4.849

Review 3.  Fluid biomarkers for mild traumatic brain injury and related conditions.

Authors:  Henrik Zetterberg; Kaj Blennow
Journal:  Nat Rev Neurol       Date:  2016-09-16       Impact factor: 42.937

Review 4.  [New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood].

Authors:  Jonathan Vogelgsang; Jens Wiltfang
Journal:  Nervenarzt       Date:  2019-09       Impact factor: 1.214

5.  Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports.

Authors:  Pashtun Shahim; Henrik Zetterberg; Yelverton Tegner; Kaj Blennow
Journal:  Neurology       Date:  2017-04-12       Impact factor: 9.910

Review 6.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

7.  A Multi-site In-depth Evaluation of the Quanterix Simoa from a User's Perspective.

Authors:  Allison Given Chunyk; Alison Joyce; Saloumeh K Fischer; Mark Dysinger; Alvydas Mikulskis; Andreas Jeromin; Rosemary Lawrence-Henderson; Dana Baker; David Yeung
Journal:  AAPS J       Date:  2017-12-01       Impact factor: 4.009

Review 8.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

9.  Gut microbiota-specific IgA+ B cells traffic to the CNS in active multiple sclerosis.

Authors:  Anne-Katrin Pröbstel; Xiaoyuan Zhou; Ryan Baumann; Sven Wischnewski; Michael Kutza; Olga L Rojas; Katrin Sellrie; Antje Bischof; Kicheol Kim; Akshaya Ramesh; Ravi Dandekar; Ariele L Greenfield; Ryan D Schubert; Jordan E Bisanz; Stephanie Vistnes; Khashayar Khaleghi; James Landefeld; Gina Kirkish; Friederike Liesche-Starnecker; Valeria Ramaglia; Sneha Singh; Edwina B Tran; Patrick Barba; Kelsey Zorn; Johanna Oechtering; Karin Forsberg; Lawrence R Shiow; Roland G Henry; Jennifer Graves; Bruce A C Cree; Stephen L Hauser; Jens Kuhle; Jeffrey M Gelfand; Peter M Andersen; Jürgen Schlegel; Peter J Turnbaugh; Peter H Seeberger; Jennifer L Gommerman; Michael R Wilson; Lucas Schirmer; Sergio E Baranzini
Journal:  Sci Immunol       Date:  2020-11-20

Review 10.  Neurofilaments in disease: what do we know?

Authors:  Brian A Gordon
Journal:  Curr Opin Neurobiol       Date:  2020-03-06       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.